Endpoints News 12 mars 2026 Novo Holdings’ assets fell by a third in 2025 as Novo Nordisk’s value sank
Endpoints News 27 févr. 2026 Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future
Endpoints News 24 févr. 2026 Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
Endpoints News 23 févr. 2026 Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
Endpoints News 9 févr. 2026 Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages
Endpoints News 4 févr. 2026 Embattled Novo Nordisk considers buying a monthly GLP-1 to bolster portfolio
Endpoints News 16 janv. 2026 Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai
Endpoints News 15 janv. 2026 A compounding pharmacy hits back at Eli Lilly, Novo Nordisk with antitrust lawsuit
Endpoints News 15 janv. 2026 FDA to meet Novo Nordisk on troubled site; AbbVie buys drug-device factory
Endpoints News 15 janv. 2026 Novo Nordisk Foundation to inject $850M+ into BioInnovation Institute through 2035
Endpoints News 12 janv. 2026 #JPM26: Novo Nordisk CEO says pharma can learn from the GLP-1 compounding boom